|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Patients (n=121)** |  |  |  |  |
| **Demographics** | **CVVHD-Citrate - only** | **CVVH-Heparin - only** | **Both modalities** | **P values** |
| Total number - no. (%) | 48 (39,7) | 30 (24,8) | 43 (35,5) | - |
| Median age - (IQR) - years | 71 (12) | 68 (11) | 69 (14) | 0.0759 |
| Median body weight - (IQR) - kg | 78,5 (27,5) | 80 (19,5) | 78 (30,2) | 0.5083 |
| Male sex - no. (%) | 37 (77,1) | 16 (53,3) | 28 (65,1) | 0.0904 |
| **Illness severty** |  |  |  |  |
| Median Charlson score - (IQR) | 6 (3,5) | 6 (3) | 5 (4) | 0.2741 |
| Median SAPS II score – (IQR) | 53.5 (18.5) | 72.5 (33.75) | 61 (19.5) | 0.0001\* |
| **Renal function parameters** |  |  |  |  |
| Mean baseline creatinine - (SD) - mol/L | 109 (71) | 91 (58,5) | 78 (29) | 0.0508 |
| Mean GFR MDRD - (SD) - ml/min/1.72m2 | 59,6 (31) | 68,1 (66,8) | 89,5 (39,8) | 0.0517 |
| **Co-existing conditions** |  |  |  |  |
| Chronic kidney injury - no. (%) | 26 (54,2) | 11 (36,7) | 11 (25,6) | 0.0193\* |
| Hemodialysis dependancy - no. (%) | 12 (25) | 3 (10) | 4 (9,3) | 0.0742 |
| Diabetes mellitus - no. (%) | 19 (39,6) | 6 (20) | 14 (32,6) | 0.1974 |
| Chronic hypertension - no. (%) | 38 (79,2) | 13 (43,3) | 23 (53,5) | 0.0030\* |
| Congestive heart failure stage I (FEVG=40-50%) - no. (%) | 6 (12,5) | 2 (6,7) | 2 (4,7) | 0.3721 |
| Congestive heart failure stage II (FEVG < 40%) - no. (%) | 5 (10,4) | 5 (16,7) | 10 (23,3) | 0.2579 |
| Peripheral arterial disease - no. (%) | 14 (29,2) | 3 (10) | 8 (18,6) | 0.1159 |
| **ICU admissions (n=126)** |  |  |  |  |
| **Diagnostic at ICU admission (1 missing)** |  |  |  |  |
| Septic shock - no. (%) | 6 (12) | 9 (29) | 14 (31,8) | 0.0511 |
| Cardiogenic shock - no. (%) | 11 (22) | 6 (19,4) | 6 (13,6) | 0.0572 |
| Hemorrhagic shock - no. (%) | 18 (36) | 1 (3,2) | 4 (9,1) | 0.0002\* |
| Cardiac arrest - no. (%) | 13 (26) | 2 (6,5) | 2 (4,5) | 0.0042\* |
| Acute kidney failure - no. (%) | 2 (4) | 0 (0) | 2 (4,5) | 0.5003 |
| Acute respiratory failure - no. (%) | 0 (0) | 0 (0) | 1 (2,3) | 0.3954 |
| Intoxication - no. (%) | 0 (0) | 5 (16,1) | 3 (6,8) | 0.0155\* |
| Others - no. (%) | 0 (0) | 8 (25,8) | 12 (27,3) | 0.0004\* |
| **Type of admission (2 missing)** |  |  |  |  |
| Medical - no. (%) | 18 (36) | 17 (56,7) | 18 (40,9) | 0.1858 |
| Surgical - no. (%) | 29 (58) | 9 (30) | 23 (52,3) | 0.0464\* |
| Others - no. (%) | 3 (6) | 4 (13,3) | 3 (6,8) | 0.0472 |

**Supplementary table 2: Characteristics of study patients according to CRRT modality groups.**

NB 1: “Both modalities” group includes patients who received both CVVH-Heparin and CVVHD-Citrate sequentially.

NB 2: CVVH-Heparin group includes circuits ran with therapeutic heparin but also sub-therapeutic and no anticoagulation at all.